4.4 Article

Rice Bran Oil Containing Gamma-Oryzanol Improves Lipid Profiles and Antioxidant Status in Hyperlipidemic Subjects: A Randomized Double-Blind Controlled Trial

Journal

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
Volume 25, Issue 3, Pages 353-358

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/acm.2018.0212

Keywords

rice bran oil; monounsaturated fatty acid; gamma-oryzanol; lipid profiles; antioxidant capacity

Funding

  1. Thai Edible Oil Co. Ltd.
  2. China Medical Board (CMB), Faculty of Public Health, Mahidol University, Bangkok, Thailand

Ask authors/readers for more resources

Objectives: Rice bran oil (RBO) is a major source of monounsaturated fatty acid and gamma-oryzanol, which may assist in lowering blood lipids and oxidative stress. This study examined the effects of RBO containing different amounts of gamma-oryzanol on blood lipid, antioxidant, and inflammatory markers. Materials and methods: A total of 59 hyperlipidemic subjects completed the study. They were divided into four groups: RBO1 (4,000ppm gamma-oryzanol, n=14), RBO2 (8,000ppm gamma-oryzanol, n=15), RBO3 (11,000ppm gamma-oryzanol, n=15), and control (soybean oil, n=15). The assigned oil (30mL) was incorporated into three cooked meals each day for 4 weeks. Anthropometrical measurements and blood samples were taken to evaluate body weight, body composition, lipid parameters, antioxidant status, and inflammatory markers before and after the intervention. Results: Compared with the control, consumption of RBO significantly decreased low-density lipoprotein cholesterol (LDL-C) levels (percentage change: -0.8% [control]; -8% [RBO1]; -11.8% [RBO2]; and -12.2% [RBO3], p=0.012) with the greatest change found in RBO2 and RBO3. In addition, antioxidant status also improved significantly. Levels of oxygen radical absorbance capacity (ORAC) and ferric reducing antioxidant power (FRAP) increased after consumption of a diet with RBO compared with consumption of a diet with soybean oil (ORAC: -2.7% [control]; 4.1% [RBO1]; 8.6% [RBO2]; and 10.1% [RBO3], p<0.001; FRAP: -4.4% [control]; 4.7% [RBO1]; 7.4% [RBO2]; and 7.6% [RBO3], p<0.001). Conclusions: RBO with gamma-oryzanol could decrease LDL-C levels and increase antioxidant capacity in hyperlipidemic subjects. Therefore, RBO consumption may reduce cardiovascular disease risk factors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available